- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192487
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea
This study is intended to evaluate:
- Any changes in the gut microbiome from baseline compared to end of study in both healthy (HIV-negative) subjects and HIV+ patients with or without chronic diarrhea, following one month of treatment with crofelemer (Mytesi), delayed release 125 mg tablets twice daily (BID) following one month of treatment.
- The safety and tolerability of crofelemer, (Mytesi) delayed release 125 mg tablets BID in healthy (HIV-negative) volunteers and HIV+ patients following one month of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mytesi ®(crofelemer) is an FDA-approved anti-diarrheal drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on combination anti-retroviral therapy (CART). Crofelemer, a first-in-class intraluminally active, use-dependent chloride (Cl-) ion channel modulator that produces an antidiarrheal effect by reducing Cl- secretion and the accompanying high-volume fluid secretion into the GI lumen.
This Phase 4 trial will explore the induced gut microbiome changes in comparison to a group of normal healthy volunteers also receiving crofelemer delayed release 125 mg tablets twice daily for 30 days.
This is a non-randomized study. The study will enroll approximately 24 male or female subjects aged at least 18 years in three cohorts of approximately 8 subjects each.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Connecticut
-
Stratford, Connecticut, United States, 06615
- Healthcare Advocates International
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01105
- The Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary informed consent from the subject to be obtained in accordance with requirements of the Institutional Review Board (IRB) before any study-related activities are performed.
- Body Mass Index (BMI) between 18 and 32 kg/m2 (both inclusive).
Females of child-bearing potential must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test at Visit 2.
Inclusion Criteria for Healthy, HIV-negative Volunteers
- No history or evidence of clinically relevant medical disorders as determined by the investigator.
No history of chronic diarrhea or loose stools and/or non-specific incidence of acute diarrhea or loose stools between the Screening Visit and Baseline Visit 2 (Day 1).
Inclusion Criteria applicable to all PLWHA subjects
- Male and female patients receiving a stable CART for ≥ 4 weeks for HIV treatment.
Have a history of diarrhea (persistently loose stools despite periodic or regular use of antimotility medications) or ≥1 watery bowel movement per day (without periodic or regular use of antimotility drugs); i.e. - diarrhea for a continuous period of ≥1 month.
Inclusion Criteria for PLWHA males and females receiving CART WITHOUT fully suppressed HIV RNA counts
- CD4 counts >200/µL at the Screening Visit.
Plasma levels of HIV RNA greater than 1,000 copies/mL at the Screening Visit.
Inclusion Criteria for PLWHA males and females receiving CART WITH fully suppressed HIV RNA counts
- CD4 counts >400/µL inclusive at the Screening Visit.
- Plasma levels of HIV RNA < 50 copies/mL at the Screening Visit.
Exclusion Criteria:
Applicable to ALL subjects
- Any serious systemic disease or infection (other than HIV in PLWHA) that occurred within four weeks prior to Screening, as determined by the Investigator.
- Patients with active bacterial or parasitic infections requiring antibiotics or antiparasitic agents will be excluded. Antibiotic or antiparasitic agents used for prophylaxis are acceptable until 7 days prior to treatment initiation.
- Stool cultures that are positive for any pathogenic infection at screening visit.
Clinically significant cardiovascular disease will include:
- History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening.
- History of or currently have New York Heart Association Class III-IV heart failure prior to Screening.
- Female subject who is pregnant or breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods.
- Subject has participated in another clinical study, involving an Investigational Product or an Investigational Device use in the past 1 month prior to commencement of this study.
- Use of Mytesi (crofelemer) within 4 weeks of the Screening Visit Applicable to ALL HIV-negative subjects
- Positive for Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody or hepatitis C antibodies (HepCAb).
- Presence or history of cancer within the past five years except for adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
Chronic diarrhea or loose stools requiring antimotility medications including, but not limited to loperamide, diphenoxylate/atropine, tincture opium and/or octreotide within 2 weeks of the Screening Visit.
Applicable to ALL PLWHA subjects
- HIV Patients with infectious diarrhea identified by either stool culture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Volunteers (HIV-negative)
Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days
|
1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
Other Names:
|
Experimental: HIV+ Patients (Fully Suppressed, Viral Load < 50c/mL)
Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
|
1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
Other Names:
|
Experimental: HIV+ Patients (Not fully suppressed viral load > 1000c/mL
Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
|
1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in gut microbiome
Time Frame: Screening (Visit 1/Day -21) to end of Study Visit 4 (Day 60)
|
Stool microbiomes will be evaluated to compare the differences in the stool microbiome at Visits 2, (Day 1) Visit 3 (Day 30) and Visit 4 (Day 60) using a proprietary microbiome statistical tool (μScope) and R statistical computing and graphics software.
|
Screening (Visit 1/Day -21) to end of Study Visit 4 (Day 60)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of reduction in the number of watery BMs
Time Frame: From baseline (Day -7) to end of study (Day 60)
|
Defined as a score of 6 or 7 on the Bristol Stool Scale
|
From baseline (Day -7) to end of study (Day 60)
|
Assessment of changes in Daily GI symptom Scale (DGIS)
Time Frame: From baseline (Day -7) to end of study (Day 60)
|
Daily presence or absence of abdominal pain, bloating, gurgling, flatulence, and bowel incontinence
|
From baseline (Day -7) to end of study (Day 60)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Smith, MD, Integrium Clinical Research
Publications and helpful links
General Publications
- Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010 Jan;77(1):69-78. doi: 10.1124/mol.109.061051. Epub 2009 Oct 6.
- Macarthur RD, Hawkins TN, Brown SJ, Lamarca A, Clay PG, Barrett AC, Bortey E, Paterson C, Golden PL, Forbes WP. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013 Nov-Dec;14(6):261-73. doi: 10.1310/hct1406-261.
- Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, Poles M. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007 May-Jun;41(5):484-90. doi: 10.1097/01.mcg.0000225694.46874.fc.
- Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. Gastroenterology. 2009 May;136(6):1952-65. doi: 10.1053/j.gastro.2008.12.073. Epub 2009 May 7. Erratum In: Gastroenterology. 2009 Jul;137(1):393.
- MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012 Sep;55(6):860-7. doi: 10.1093/cid/cis544. Epub 2012 Jun 14.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Signs and Symptoms, Digestive
- Slow Virus Diseases
- HIV Infections
- Diarrhea
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
Other Study ID Numbers
- NP 303-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acquired Immunodeficiency Syndrome
-
VA Eastern Colorado Health Care SystemPublic Health Grant Program, Veterans Health Administration Office of Public...CompletedHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) | Self-Directed ViolenceUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus | Acquired Immune Deficiency Syndrome Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus | Human Immunodeficiency VirusesUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH); Ministry of Health and Social Welfare...CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)Tanzania
-
Janssen-Cilag International NVCompletedHIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS VirusUnited Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
-
Emory UniversityGrady Health SystemCompleted
-
Columbia UniversityNational Institute of Nursing Research (NINR)CompletedHIV (Human Immunodeficiency Virus) | AIDS (Acquired Immunodeficiency Syndrome)United States
-
St. Jude Children's Research HospitalCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immunodeficiency Syndrome (AIDS)United States
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Columbia UniversityNational Institute of Mental Health (NIMH)CompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)Ethiopia
-
Columbia UniversityCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)South Africa
Clinical Trials on Crofelemer delayed-release tablets 125mg
-
Teva Pharmaceuticals USACompleted
-
Mylan Pharmaceuticals IncCompleted
-
Teva Pharmaceuticals USACompleted
-
TakedaCompleted
-
Alfasigma S.p.A.CromsourceTerminated
-
Synthetic Biologics Inc.Spaulding Clinical Research LLCCompletedEnteritis Caused by RadiationUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
PfizerCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Synthetic Biologics Inc.Spaulding Clinical Research LLCCompletedEnteritis Caused by Radiation (Disorder)United States